ENHANCE HEALTH EXPANDS LEADERSHIP TEAM FOR OPERATIONS AND REGULATORY AFFAIRS
- "Shawn and Christopher's firsthand experience and expertise will be instrumental in scaling our business."
Shawn Holt , Chief Operating Officer: Previously the Chief Sales Officer at Ambetter & Wellcare/Centene Corporation, Shawn will assume responsibility for sales, customer service, and carrier relations. Shawn will report toMatthew Herman , CEO and President of Enhance Health. Christopher Nicolopoulos , Vice President of Government Affairs: Christopher joins Enhance Health after serving as theNew Hampshire Commissioner of Insurance. In his role, he will oversee strategic planning and engagement objectives, growing Enhance's direct government programs at all levels. Christopher will report toGeorge Lyford , Chief Compliance Officer and Deputy General Counsel.
Founded in 2021 by industry veteran
"We have assembled the industry's most experienced executive team, composed of individuals with exceptional track records in the insurance space," stated
About Enhance Health: Started in 2021 with a capital commitment led by Bain Capital Insurance, Enhance Health has expanded exponentially as a record number of Americans enrolled in ACA health plans in 2022. With the end of the Covid-19 Public Health Emergency, the company's licensed agents will also help enroll people who no longer qualify for Medicaid into ACA health plans. Enhance Health also offers a full range of other insurance products, including dental, Medicare, and life insurance plus their proprietary Enhance HealthRx discount card. Visit https://enhancehealth.com/about-us/ for more information.
View original content to download multimedia:https://www.prnewswire.com/news-releases/enhance-health-expands-leadership-team-for-operations-and-regulatory-affairs-301875810.html
SOURCE Enhance Health
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hanwha Power Marks U.S. Market with Successful Commissioning of Trumbull Energy Center CCGT
- New High-Grade Uranium Discovery Identified at PLS Project
- Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Bain CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share